AXSOME THERAPEUTICS, INC. Share-based Payment Arrangement, Amount Capitalized
AXSOME THERAPEUTICS, INC. (AXSM) reported Share-based Payment Arrangement, Amount Capitalized of $400.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2026-06-30 was $400.00K, a 33.33% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2026-03-31 was $500.00K, a 66.67% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-12-31 was $500.00K, a 66.67% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-09-30 was $300.00K, a 0.00% change year-over-year.
- AXSOME THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2025 was $1.50M, a 15.38% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2024 was $1.30M, a 51.85% decline from fiscal 2023.
- AXSOME THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2023 was $2.70M, a 107.69% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. share-based payment arrangement, amount capitalized for fiscal 2022 was $1.30M.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-08-10 | $900.00K 10-Q · filed 2026-08-10 | $1.40M derived: sum of 3 quarters · filed 2026-08-10 | $1.70M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-04 | $1.00M derived: sum of 2 quarters · filed 2026-05-04 | $1.30M derived: sum of 3 quarters · filed 2026-05-04 | $1.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $800.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.10M derived: sum of 3 quarters · filed 2026-08-10 | $1.50M 10-K · filed 2026-02-23 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-03 | $600.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.00M 10-Q · filed 2025-11-03 | $1.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-10 | $700.00K 10-Q · filed 2026-08-10 | $900.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-04 | $600.00K derived: sum of 2 quarters · filed 2026-05-04 | $900.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.20M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $600.00K derived: sum of 2 quarters · filed 2026-02-23 | $900.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.30M 10-K · filed 2026-02-23 |
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-03 | $600.00K derived: sum of 2 quarters · filed 2025-11-03 | $1.00M 10-Q · filed 2025-11-03 | $1.20M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-04 | $700.00K 10-Q · filed 2025-08-04 | $900.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.80M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-05 | $600.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.50M derived: sum of 3 quarters · filed 2026-02-23 | $2.40M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.20M derived: sum of 2 quarters · filed 2026-02-23 | $2.10M derived: sum of 3 quarters · filed 2026-02-23 | $2.70M 10-K · filed 2026-02-23 |
| 2023-09-30 | $900.00K 10-Q · filed 2024-11-12 | $1.80M derived: sum of 2 quarters · filed 2024-11-12 | $2.40M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $900.00K 10-Q · filed 2024-08-05 | $1.60M 10-Q · filed 2024-08-05 | ||
| 2023-03-31 | $700.00K 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $1.30M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |